key: cord-0733378-l0l2ev29 authors: Chai, Qing; Nygaard, Ulrikka; Schmidt, Rebecca Catherine; Zaremba, Tomas; Møller, Anne Marie; Thorvig, Camilla Maria title: Multisystem inflammatory syndrome in a male adolescent after his second Pfizer‐BioNTech COVID‐19 vaccine date: 2021-10-28 journal: Acta Paediatr DOI: 10.1111/apa.16141 sha: d59c063b0a606f0a9741889b71775b220fa659f9 doc_id: 733378 cord_uid: l0l2ev29 Multisystem inflammatory syndrome (MIS) in children (MIS-C) is a complication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, while myocarditis is a rare adverse effect to messenger ribonucleic acid (mRNA) SARS-CoV-2 vaccines, especially in males aged 12-17 years. Multisystem inflammatory syndrome (MIS) in children (MIS-C) is a complication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, while myocarditis is a rare adverse effect to messenger ribonucleic acid (mRNA) SARS-CoV-2 vaccines, especially in males aged 12-17 years. 1, 2 As far as we are aware, no cases of MIS-C after mRNA SARS-CoV-2 vaccinations have been reported in children or adolescents. However, 1 case of MIS after the Pfizer-BioNTech mRNA vaccine has been described in a 44-year-old woman without a previous SARS-CoV-2 infection. 3 We present details on a 17-year-old previously healthy male adolescent who fulfilled the diagnostic criteria for MIS-C after the Pfizer-BioNTech vaccine. 4 He developed fever, vomiting, myalgia and chest pain 5 days after his second dose of the Pfizer-BioNTech vaccination. After 2 days, he was admitted to hospital with high levels of inflammatory parameters and multisystem involvement of the gastrointestinal tract, skin, central nervous system, kidneys, liver, coagulation, lungs and heart ( Table 1 ). The patient developed myocarditis, with a severely reduced ejection fraction of 20%. He received therapy in the intensive care unit for 6 days with norepinephrine infusion, high-flow oxygen therapy, steroids, intravenous immunoglobulin and antibiotics. The patient was discharged after 10 days of hospitalisation. Cardiac magnetic resonance imaging the day after discharge revealed normal left ventricular ejection fraction of 62% and was consistence with myocarditis with subepicardial late gadolinium enhancement. During a follow-up visit 8 days after discharge, the patient was asymptomatic, except fatigue, with no obvious clinical sequelae (Table 1) . He returned to school the week after discharge from the hospital. In-depth investigations excluded a wide range of differential diagnoses, including septic shock and toxic shock syndrome, men- The patient developed the first symptoms 2 days before hospitalisation (5 days after the second vaccine). Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices -United States COVID-19 vaccination-associated myocarditis in adolescents Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V) Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data Multisystem inflammatory syndrome in children occurred in one of four thousand children with severe acute respiratory syndrome coronavirus 2